21.73
-1.59%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mabwell Shanghai Bioscience Co
Its shares trade on Shanghai under the ticker 688062.SS. It has been listed since 18 January 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥662.5m and a net loss of CN¥970.2m. At that date it held total assets of CN¥4.56bn and shareholders' equity of CN¥349.5m.
Mabwell (Shanghai) Bioscience Co., Ltd. engages in the research and development, production and sales of therapeutic biological products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-01-18. The firm's main businesses include the establishment of new varieties of drugs and the discovery of some early projects, the organization and development of preclinical research and pharmacological effects, and the development of drugs for preclinical research. The firm is also engaged in the organization, management and development of clinical trials of research species. The firm's research on drugs covers autoimmune, tumor, metabolism, ophthalmology, infection and other disease fields. The firm conducts business in domestic and foreign markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Jan 2022
- Employees
- 1,052
- Website
- mabwell.com ↗
Leadership
Pay as last reported
- Mr. Chunshan TangExecutive Chairman of the Board, since 2020
- Mr. Hai WuDevelopment President, Deputy General Manager, Executive Director
- Ms. Yin YeFinance Director
- Dr. Xin DuChief Scientific Officer
- Mr. Datao LiuGeneral Manager, Executive Director
- Mr. Huiguo HuDeputy General Manager, Executive Director, Secretary of the Board, since 2021
- Ms. Xi ChenDeputy General Manager
- Mr. Weiyi DongDeputy General Manager
- Mr. Han LiDeputy General Manager
- Mr. Hua NiDeputy General Manager
- Dr. Shuhai WangDeputy General Manager, since 2020
- Mr. Xun GuiExecutive Director, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mabwell Shanghai Bioscience employs 1052 employees in Health Care biotechnology.
- Mabwell's therapeutic biological products cover autoimmune, tumor, and metabolic disease fields.
- Mabwell conducts clinical trials for research species in domestic and foreign markets.
Weaknesses
- Mabwell's IPO was on 18 January 2022, a relatively recent listing.
- Mabwell's business is limited to therapeutic biological products without diversification.
- Mabwell's research spans multiple disease fields but lacks specific drug approvals.
Opportunities
- Mabwell can expand into ophthalmology and infection disease fields for new drug development.
- Mabwell's domestic and foreign market presence offers growth potential in global health care.
- Mabwell's preclinical research development can lead to new therapeutic biological products.
Threats
- Mabwell faces competition in the Health Care biotechnology sector for drug development.
- Mabwell's reliance on preclinical research may delay drug approvals and market entry.
- Mabwell's focus on multiple disease fields could lead to resource allocation challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.